BellRing Brands (BRBR)
(Delayed Data from NYSE)
$63.19 USD
+0.44 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.18 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.19 USD
+0.44 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $63.18 -0.01 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
Zacks News
Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System
by Zacks Equity Research
Thermo Fisher's (TMO) Nano-Capillary and Micro-Flow LC Systems will benefit principal investigators, laboratories and proteomics researchers in academia, biopharma and contract research organizations.
What Makes BellRing Brands (BRBR) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does BellRing Brands (BRBR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Medtronic's (MDT) Emprint Ablation System Study Data Positive
by Zacks Equity Research
Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.
Abbott (ABT) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on solid second-quarter performance and continued adoption of FreeStyle Libre worldwide.
Earnings Estimates Rising for BellRing Brands (BRBR): Will It Gain?
by Zacks Equity Research
BellRing Brands (BRBR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx
by Zacks Equity Research
Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.
QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat
by Zacks Equity Research
QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.
Should Value Investors Buy BellRing Brands (BRBR) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump
by Zacks Equity Research
The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.
Abbott (ABT) Expands Vascular Portfolio With New Acquisition
by Zacks Equity Research
Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.
Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line
by Zacks Equity Research
Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.
Smith+Nephew (SNN) Releases New Features for Hip Arthroplasty
by Zacks Equity Research
Smith+Nephew (SNN) introduced the RI.HIP NAVIGATION software on the CORI Surgical System and announced the commercial availability of RI.INSIGHTS at the AAOS 2021 Annual Meeting.
Orthofix (OFIX) Fitbone Used in 1st US Pediatric Patient Implant
by Zacks Equity Research
Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable (Revised)
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.
Zimmer Biomet's (ZBH) Data Favors mymobility with Apple Watch
by Zacks Equity Research
Zimmer Biomet (ZBH) presented four data presentations backing the mymobility with Apple Watch platform at the AAOS 2021 Annual Meeting.
Walgreens (WBA) to Stock LUCEMYRA Across US With New Pact
by Zacks Equity Research
Walgreens' (WBA) agreement with US WorldMeds finalized as recent report outlines a surge of 30% in drug overdose deaths in 2020.
Cardiovascular Systems (CSII) Introduces Diamondback in Canada
by Zacks Equity Research
The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.
Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable
by Zacks Equity Research
Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.
Hill-Rom (HRC) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on impressive third-quarter fiscal 2021 performance and raised 2021 guidance.
Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario
by Zacks Equity Research
LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Medtronic's (MDT) Micra TPS CED Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges
by Zacks Equity Research
According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.